0000899243-20-027297.txt : 20201005 0000899243-20-027297.hdr.sgml : 20201005 20201005170010 ACCESSION NUMBER: 0000899243-20-027297 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200716 FILED AS OF DATE: 20201005 DATE AS OF CHANGE: 20201005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arix Bioscience plc CENTRAL INDEX KEY: 0001700449 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38707 FILM NUMBER: 201224284 BUSINESS ADDRESS: STREET 1: 20 BERKELEY SQUARE CITY: LONDON STATE: X0 ZIP: W1J 6EQ BUSINESS PHONE: 44(0)20 7290 1050 MAIL ADDRESS: STREET 1: 20 BERKELEY SQUARE CITY: LONDON STATE: X0 ZIP: W1J 6EQ REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arix Bioscience Holdings Ltd CENTRAL INDEX KEY: 0001756884 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38707 FILM NUMBER: 201224285 BUSINESS ADDRESS: STREET 1: 20 BERKELEY SQUARE CITY: LONDON STATE: X0 ZIP: W1J6EQ BUSINESS PHONE: 44(0)20 7290 1050 MAIL ADDRESS: STREET 1: 20 BERKELEY SQUARE CITY: LONDON STATE: X0 ZIP: W1J6EQ ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc. CENTRAL INDEX KEY: 0001664106 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471514975 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-245-0399 MAIL ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-16 0 0001664106 LogicBio Therapeutics, Inc. LOGC 0001700449 Arix Bioscience plc 20 BERKELEY SQUARE MAYFAIR, LONDON X0 W1J6EQ UNITED KINGDOM 0 0 1 0 0001756884 Arix Bioscience Holdings Ltd 20 BERKLEY SQUARE MAYFAIR, LONDON X0 W1J6EQ UNITED KINGDOM 0 0 1 0 Common stock 2020-07-16 4 S 0 16332 8.559 D 2962691 I See footnote Common stock 2020-07-17 4 S 0 31101 9.24 D 2931590 I See footnote Common stock 2020-07-20 4 S 0 36983 9.249 D 2894607 I See footnote Common stock 2020-07-22 4 S 0 22651 9.004 D 2871956 I See footnote Common stock 2020-07-29 4 S 0 2709 8.781 D 2869247 I See footnote Common stock 2020-08-12 4 S 0 1335 8.79 D 2867912 I See footnote Common stock 2020-08-13 4 S 0 159 8.75 D 2867753 I See footnote Common stock 2020-09-24 4 S 0 38514 7.629 D 2829239 I See footnote Common stock 2020-09-25 4 S 0 174219 7.077 D 2655020 I See footnote Common stock 2020-09-28 4 S 0 273584 7.5365 D 2381436 I See footnote Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.685 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer. These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.415 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.05 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.91 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.35 to $7.70 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.00 to $8.15 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.75 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer. Arix Bioscience Plc, by: /s/ Marcus Karia, Authorized Officer 2020-10-05 Arix Bioscience Holdings Limited, by: /s/ Marcus Karia, Authorized Officer 2020-10-05